A USFDA-inspected CDMO experienced in developing sustainable processes for late phase to commercial small molecule and peptide APIs with a proven track record of taking projects from development to commercial scale. Founded in 1995, Asymchem has 7 sites across P.R. China and an enabling technology platform in continuous flow and biocatalysis, with a specialized facility for the development and GMP manufacture of HPAPI, including cytotoxic and β-lactams. Capabilities and experience in hazardous chemistry applications includes ozonolysis, hydrogenation, and other high temperature and high-pressure reactions. Asymchem has a research group dedicated to process optimization, process design space characterization (PAR/NOR), and manufacturing of peptides and peptide-containing drugs.
|Affiliated categories:||Advanced Intermediates |Amino Acids |Antibiotics More|
News about Asymchem, Inc.
8 Mar 2019
Asymchem Takes New Step on Application of Continuous Reaction
Asymchem has become a global leader in the pharmaceutical CDMO industry. Asymchem has been committed to the development and commercial application of green pharmaceutical technologies for many years.Read more
8 Mar 2019
Asymchem is awarded as “2018 Best Partner of China Pharmaceutical Enterprises in Transformation and Upgrading”
The 2019 China Pharma New Year Forecast was successfully held in Beijing by the Healthcare Executive and China Healthcare Industry Investment Forum, supported by the China Pharmaceutical Enterprises Association on January 19.Read more
Categories affiliated with Asymchem, Inc.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation